| 0.8933 0.087 (10.82%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.1 |
1-year : | 1.29 |
| Resists | First : | 0.94 |
Second : | 1.1 |
| Pivot price | 0.79 |
|||
| Supports | First : | 0.79 |
Second : | 0.69 |
| MAs | MA(5) : | 0.8 |
MA(20) : | 0.78 |
| MA(100) : | 0.71 |
MA(250) : | 0.77  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 68.5 |
D(3) : | 53 |
| RSI | RSI(14): 62.5 |
|||
| 52-week | High : | 2.04 | Low : | 0.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HOOK ] has closed below upper band by 0.6%. Bollinger Bands are 2.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.95 | 0.95 - 0.96 |
| Low: | 0.77 - 0.77 | 0.77 - 0.78 |
| Close: | 0.89 - 0.89 | 0.89 - 0.9 |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Thu, 25 Apr 2024
Why HOOKIPA (HOOK) Stock Might be a Great Pick - Yahoo Movies Canada
Wed, 24 Apr 2024
Hookipa stock gains as Roche to pay $10M (NASDAQ:HOOK) - Seeking Alpha
Wed, 24 Apr 2024
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? - HOOKIPA Pharma (NASDAQ:HOOK) - Benzinga
Wed, 24 Apr 2024
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment ... - Yahoo Finance
Mon, 22 Apr 2024
Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts - Seeking Alpha
Sun, 24 Mar 2024
Time To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Outlook - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 19.5 (%) |
| Held by Institutions | 39.3 (%) |
| Shares Short | 316 (K) |
| Shares Short P.Month | 299 (K) |
| EPS | -0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.91 |
| Profit Margin | 0 % |
| Operating Margin | -244.8 % |
| Return on Assets (ttm) | -32 % |
| Return on Equity (ttm) | -84.9 % |
| Qtrly Rev. Growth | -5.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.2 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -58 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -1.04 |
| PEG Ratio | -0.2 |
| Price to Book value | 0.98 |
| Price to Sales | 4.28 |
| Price to Cash Flow | -1.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|